Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Karen So · SciRah

Researcher profile · Semantic Scholar

Karen So

Share profile

Karen So — researcher profile on SciRah

h-index: 19
Works: 43
Citations: 1,266

Most-cited papers

Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
M. Ferguson, Jonathan A. L. Duncan, Jeremy S. Bond, J. Bush +11 more
2009The Lancet273 citations
Semantic Scholar
Interleukin‐10 reduces scar formation in both animal and human cutaneous wounds: Results of two preclinical and phase II randomized control studies
I. Kieran, A. Knock, J. Bush, Karen So +5 more
2013Wound Repair and Regeneration112 citations
Semantic Scholar
Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial
Karen So, D. McGrouther, J. Bush, P. Durani +6 more
2011Plastic and Reconstructive Surgery106 citations
Semantic Scholar
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
K. Vishwanathan, Paul A. Dickinson, Karen So, K. Thomas +10 more
2018British Journal of Clinical Pharmacology62 citations Open access
Semantic Scholar
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
A. Ho, M. Dedecjus, L. Wirth, R. Tuttle +14 more
2022Journal of Clinical Oncology56 citations Open access
Semantic Scholar
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers
K. Vishwanathan, Paul A. Dickinson, K. Bui, P. Cassier +8 more
2018Journal of clinical pharmacology55 citations
Semantic Scholar
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
R. Plummer, H. Swaisland, K. Leunen, C. V. van Herpen +11 more
2015Cancer Chemotherapy and Pharmacology53 citations
Semantic Scholar
Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial
J. Bush, Jonathan A. L. Duncan, Jeremy S. Bond, P. Durani +4 more
2010Plastic and Reconstructive Surgery53 citations
Semantic Scholar
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
L. Dirix, H. Swaisland, H. Verheul, S. Rottey +14 more
2016Clinical Therapeutics49 citations Open access
Semantic Scholar
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors
C. Rolfo, H. Swaisland, K. Leunen, A. Rutten +7 more
2015Advances in Therapy41 citations Open access
Semantic Scholar
Absolute Bioavailability of Osimertinib in Healthy Adults
K. Vishwanathan, Karen So, K. Thomas, A. Bramley +2 more
2019Clinical pharmacology in drug development33 citations
Semantic Scholar
Remote Wound Monitoring of Chronic Ulcers
Sonja A. Weber, N. Watermann, J. Jossinet, J. Byrne +6 more
2010IEEE Transactions on Information Technology in Biomedicine30 citations
Semantic Scholar
Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
A. Dymond, C. Howes, C. Pattison, Karen So +5 more
2016Clinical Therapeutics28 citations Open access
Semantic Scholar
Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
A. Dymond, Karen So, Paul D. Martin, Yi-Fan Huang +4 more
2016European Journal of Clinical Pharmacology27 citations Open access
Semantic Scholar
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
A. Greystoke, Nicola Steele, H. Arkenau, F. Blackhall +11 more
2017British Journal of Cancer25 citations Open access
Semantic Scholar
Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
R. D. Harvey, N. R. Aransay, N. Isambert, Jong-Seok Lee +8 more
2018British Journal of Clinical Pharmacology24 citations Open access
Semantic Scholar
Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring
J. Bush, Karen So, T. Mason, N. Occleston +2 more
2010Dermatology research and practice22 citations Open access
Semantic Scholar
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment
E. Grande, R. Harvey, B. You, J. Batlle +7 more
2019Journal of Pharmacology and Experimental Therapeutics20 citations
Semantic Scholar
Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study
S. Suenobu, K. Terashima, M. Akiyama, T. Oguri +5 more
2023Neuro-Oncology Advances19 citations Open access
Semantic Scholar
Effects of interleukin‐10 on cutaneous wounds and scars in humans of African continental ancestral origin
I. Kieran, Catherine Taylor, J. Bush, M. Rance +7 more
2014Wound Repair and Regeneration18 citations
Semantic Scholar
Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
A. Dymond, C. Elks, Paul D. Martin, D. Carlile +6 more
2017European Journal of Clinical Pharmacology15 citations Open access
Semantic Scholar
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
H. Swaisland, R. Plummer, Karen So, S. Garnett +4 more
2016Cancer Chemotherapy and Pharmacology15 citations
Semantic Scholar
Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
A. Dymond, Paul D. Martin, Karen So, Yi-Fan Huang +4 more
2016Journal of clinical pharmacology14 citations Open access
Semantic Scholar
Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event
M. S. Tackney, Amber Steele, Joseph Newman, Marie-Christine Fritzsche +24 more
2024Trials13 citations Open access
Semantic Scholar
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas
S. Schalkwijk, Li Zhou, Sarit Cohen‐Rabbie, Lokesh Jain +7 more
2021Cancer Chemotherapy and Pharmacology13 citations
Semantic Scholar
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
H. Tomkinson, E. McBride, Paul D. Martin, E. Lisbon +4 more
2017Clinical Therapeutics13 citations
Semantic Scholar
Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291
K. Vishwanathan, P. Dickinson, K. Bui, D. Weilert +4 more
201510 citations
Semantic Scholar
Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts
T. Bauer, K. Moore, J. Rader, Fiona Simpkins +15 more
2019Clinical Trials9 citations
Semantic Scholar
VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.
A. Tutt, C. Stephens, P. Frewer, A. Pierce +5 more
20189 citations
Semantic Scholar
Effect of food on capsule and granule formulations of selumetinib
Sarit Cohen‐Rabbie, Alexandra Mattinson, Karen So, Nan Wang +1 more
2022Clinical and Translational Science8 citations Open access
Semantic Scholar
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
M. Någård, M. Ah-See, Karen So, M. Vermunt +9 more
2020Cancer Chemotherapy and Pharmacology8 citations Open access
Semantic Scholar
Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.
R. Harvey, N. Isambert, S. Rafii, J. Vansteenkiste +6 more
20168 citations
Semantic Scholar
Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.
I. Vergote, A. Rutten, C. Rolfo, P. Soetekouw +7 more
20146 citations
Semantic Scholar
Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Dian-Song Zhou, Karen So, A. Dymond, T. Vik +8 more
2016Clinical Therapeutics4 citations Open access
Semantic Scholar
A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.
Sarit Cohen‐Rabbie, Alexandra Mattinson, Karen So, Nan Wang +1 more
2022Clinical Therapeutics3 citations
Semantic Scholar
Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
K. Vishwanathan, M. Cantarini, Karen So, E. Masson +3 more
2019Clinical and Translational Science3 citations Open access
Semantic Scholar
CTNI-09. A PHASE I HEALTHY VOLUNTEER STUDY ON THE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF CAPSULE AND GRANULE FORMULATIONS OF SELUMETINIB
Sarit Cohen‐Rabbie, Alexandra Mattinson, Karen So, Nan Wang +3 more
20202 citations Open access
Semantic Scholar
Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).
K. Vishwanathan, J. Yang, J. S. Lee, M. Krebs +6 more
20162 citations
Semantic Scholar
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib table formulation in patients with advanced solid tumors : phase I open-label studies
E. Plummer, H. Verheul, S. Rottey, K. Leunen +14 more
20152 citations
Semantic Scholar
Abstract 3035: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors
M. Någård, M. Ah-See, Karen So, J. Strauss +9 more
2020Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Abstract 591: Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study
M. Någård, M. Ah-See, Karen So, J. Strauss +11 more
2020Experimental and Molecular Therapeutics1 citations
Semantic Scholar
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting
E. Dean, Nicola Steele, H. Arkenau, F. Blackhall +11 more
20161 citations Open access
Semantic Scholar
Avotermin: emerging evidence of efficacy for the improvement of scarring
J. Bush, Karen So, T. Mason, N. Occleston +2 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Vishwanathan×11
Invite
K. Vishwanathan — researcher profile on SciRah
J. Bush×8
Invite
J. Bush — researcher profile on SciRah
A. Dymond×8
Invite
A. Dymond — researcher profile on SciRah
S. O'Kane×7
Invite
S. O'Kane — researcher profile on SciRah

×7

Invite

K. Thomas — researcher profile on SciRah

Invite

T. Mason — researcher profile on SciRah

Invite

K. Bui — researcher profile on SciRah

Invite

D. Weilert — researcher profile on SciRah

Invite

R. Plummer — researcher profile on SciRah

H. Swaisland×6

Invite

H. Swaisland — researcher profile on SciRah

Invite

A. Fielding — researcher profile on SciRah

Paul D. Martin×6

Invite

Paul D. Martin — researcher profile on SciRah